Richard J. Meadows
Board Member
Q: Why do you volunteer on the Board of the Ottawa Hospital Research Institute?
A: The Ottawa Hospital Research Institute operates at the intersection of excellent science, committed management, compassionate clinicians and public need. Each of us regardless of our circumstances, will, at some juncture of our lives face a health problem. I believe that it is my distinct privilege to facilitate, in any way I can, the world class researchers of The Ottawa Hospital to find innovative solutions to those disease challenges and bring them forward to benefit those who need it most.
Richard Meadows was selected by FORBES Magazine as one of the top ten Life Science Investors in North America in 2013.
Richard was a Managing Partner and one of the co-founders of CTI Life Sciences Fund, a successful Quebec-based Cdn.$100 million biotechnology, pharmaceutical and medical devices investment fund (CTI I vintage 2007). He joined CTI from his previous position as a Venture Partner with VantagePoint Venture Partners, a US$2.8 billion private equity fund based in San Bruno, California. Richard was also a Partner in the Biotechnology Group of CDP Capital Technology Ventures, a Cdn.$1.2 billion fund affiliated with the Caisse de Depot et Placement du Quebec. A few examples of some of his exits:
- ENOBIA Pharma – acquired by ALEXION for $1.081B
- TARGEGEN – acquired by Sanofi Aventis for $575M
- EXEMIAS Therapeutics – reverse merger into YM Biosciences; just before its acquisition by GILEAD for $510M
- CGI Pharma acquired by GILEAD for $125M
Mr. Meadows has extensive experience in operations, clinical development, general management and finance in the biotechnology and medical device sectors. He has made, managed and exited numerous investments in the cancer, cardiovascular, auto-inflammatory, central nervous system, orphan disease, orthopaedic, medical diagnostic and immunology areas. He has represented venture capital and private equity investors on some 20+ corporate boards of directors.
Richard received his undergraduate degree in Biochemistry and a M.Sc. in Cardiovascular Physiology, both from McGill University. Richard is also a graduate of the Rotman School of Management, University of Toronto where he received his M.B.A. and a Certificate in Financial Strategy.
